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Abstract
Objectives: The aim of this study is to investigate the effect of 
eicosapentaenoic acid combined with vitamin C in comparison with 
the pure form of eicosapentaenoic acid on the serum concentration 
of malondialdehyde, erythrocyte activity of superoxide dismutase, 
glutathione peroxidase, and the serum level of total antioxidant 
capacity in patients with type 2 diabetes.
Methods: Eighty one male diabetic patients, aged 33-63 years, 
were randomly assigned to one of 4 groups. The subjects consumed 
500 mg/d pure eicosapentaenoic acid, 200 mg/d vitamin C, 500 
mg eicosapentaenoic acid and 200 mg/d vitamin C or placebo 
depending on their groups. In fasting blood samples, superoxide 
dismutase and glutathione peroxidase activities were determined via 
the enzymatic method (Randox kit) and the serum total antioxidant 
capacity, malondialdehyde and vitamin C concentrations were 
estimated by colorimetric methods.
Results: Administration of pure eicosapentaenoic acid in 
diabetic patients increased superoxide dismutase by 4%, 
glutathione peroxidase 53%, total antioxidant capacity 36% and 
decreased malondialdehyde significantly by 25%. Prescription of 
eicosapentaenoic acid combined with vitamin C demonstrated a 
significant increment for superoxide dismutase activity by 3% and 
for glutathione peroxidase activity by 52% during the study, but 
no significant change was seen for total antioxidant capacity and 
malondialdehyde, respectively. There was a significant decrease in 
FBS and HbA1c following prescription of eicosapentaenoic acid 
with/without vitamin C along the study, although these changes 
were not significant between the study groups.
Conclusion: It is concluded that prescription of eicosapentaenoic 
acid in the pure form reduces oxidative stress in type 2 diabetic 
patients; albeit, it does not alleviate hyperglycemia. Combination of 
vitamin C and eicosapentaenoic acid does not improve antioxidant 
property of eicosapentaenoic acid.
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Introduction
Diabetes mellitus, recognized by elevation of blood glucose 
concentration and lipid abnormalities, is accompanied by 
mitochondrial oxidative injuries.1 It has been reported that excessive 
blood glucose or FFAs trigger the development of reactive oxygen 
species (ROS) in muscle and adipose tissue.2-4 Oxidative injuries 
will possibly be the reason for cell dysfunction in diabetic patients.5,6 
β-cells are also compromised from oxidative damage and β-cell 
apoptosis will be induced by the superoxide anions.5
Superoxide anions are enzymatically transformed to hydrogen 
peroxide by superoxide dismutase (SOD) within mitochondria 
and then hydrogen peroxide can be quickly removed by the 
mitochondrial enzyme glutathione peroxidase (GPx).7 Imbalance 
between the formation and break down of superoxide anions by 
mitochondrial enzymes in diabetes results in atherosclerosis and 
microvascular complications.8,9 Prescription of antioxidants such 
as vitamins C, E, lipoic acid and glutathione can reduce superoxide 
anions via modulating anti oxidant enzymes (SOD and GPx) 
activity.10-12
There are several reports that indicate n-3 fatty acid prescription 
increases antioxidant enzymes as well as reducing the risk of 
atherosclerosis in human studies,13,14 although some literature have 
shown an augmented lipid peroxidation susceptibility because of 
the high double bound content of n-3 fatty acids.15 These studies 
were based primarily on the results of the thiobarbituric acid 
assay (TBA) to asses malodialdehyde (MDA) level as a marker 
of highly unsaturated n-3 fatty acids oxidation.16 Ghiasvand et al. 
reported a significant increase in MDA after EPA supplementation 
in basketball players, where the concentration of MDA remained 
unchanged during the study in those treated with EPA combined 
with vitamin E.17
This current study, based on the incorporation of highly 
unsaturated n-3 fatty acids in lipid peroxidation,18 and the 
involvement of vitamin C in reducing the lipid peroxidation in 
diabetic patients,19 was prepared to investigate the effect of EPA 
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combined with vitamin C in comparison with the pure form of EPA 
on the serum concentration of MDA, serum activity of SOD and 
GPx, as well as serum total antioxidant capacity (TAC) in patients 
with type 2 diabetes.
Methods
One hundred male subjects with type 2 diabetes, aged 33-63 
years, were recruited from the public by media advertising. Entry 
criteria included: body mass index (in kg/m2) <35, no special diet, 
and no previous medical history of thyroid, liver, renal or chronic 
inflammatory diseases. None of the subjects were regularly taking 
lipid-lowering, beta-adrenergic antagonist or thiazide diuretic 
drugs. None of the subjects took fish oil supplements. Subjects were 
excluded if they had a recent history (within 3 months) of heart 
disease, angina, or major surgery; had a recent history (within 6 
months) of myocardial infarction or stroke; had significant liver or 
renal disease (plasma creatinine >130 mol L-1), macroproteinuria, 
or symptomatic autonomic neuropathy; or regularly used 
nonsteroidal anti-inflammatory drugs. Eighty-one out of the total 
100 subjects screened satisfied the entry criteria and completed the 
study. The study was approved by the Ethics Committee at Tehran 
University of Medical Sciences, and the reported investigations were 
carried out in accordance with the principles of the Declaration of 
Helsinki as revised in 2000. Informed consent was obtained from 
all individuals. The participants were instructed not to take any 
n-3 fatty acids and antioxidant supplements during and 8 weeks 
preceding the study.
Baseline measurements were collected during a 3-week period, 
during which all subjects maintained their usual diet. They were 
randomly assigned to one of the 4 groups after stratification by age 
and body mass index. All participants received 2 soft gel capsules 
daily for 8 weeks: Group 1 took 500 mg EPA and the placebo of 
vitamin C; Group 2 received 200 mg vitamin C and the placebo of 
EPA; Group 3 was administered 500 mg EPA plus 200 mg vitamin 
C; and Group 4 was administered the corresponding placebo 
respectively. The details of the soft gels consumed in each group are 
given in Table 1. The subjects consumed EPA and/or vitamin C or 
placebo depending on their groups while continuing to consume 
their usual diet. EPA and the corresponding placebo soft gels were 
supplied from Minami Nutrition (Belgium). Vitamin C and the 
corresponding placebo soft gels were obtained from Darou Pakhsh 
Pharma Chem. Co., (Iran).
Subjects and investigators were blinded to the treatment. 
Subjects were instructed not to change their usual diets, level of 
physical activity, or other lifestyle factors throughout the intervention 
period. Before the baseline period, a dietitian gave written and verbal 
instructions to the subjects on how to keep accurate dietary records, 
including how to weigh or measure food. A 3-day dietary record (2 
week days and 1 weekend day) and a lifestyle questionnaire including 
history of illness, medications and physical activity were completed 
at baseline and after the intervention period. Physical activities 
of participants were evaluated by a questionnaire based on the 
International Physical Activity Questionnaire, 2005 Epic-Norfolk. 
Each food and beverage was analyzed for content of energy and 
other nutrients using NUNTRITIONIST III software (version 
7.0; N-Squared Computing, Salem, OR), which was designed for 
Iranian foods. Weight and height of subjects were measured by a 
digital scale and non-stretchable meter. Weight, changes in physical 
activity, medication, and any illness were recorded each week during 
baseline and at weeks 2, 4, 6 and at the end of the intervention.
For the biochemical measurements, fasting blood samples were 
taken at baseline and at the end of the 8 week study; all EDTA 
treated blood samples were promptly centrifuged. Plasma and 
erythrocytes were separated and erythrocytes were washed three 
times with 0.9% NaCl solution, and then hemolyzed with four 
volumes of cold distilled water. Analyses were carried out at the 
laboratory of the department of nutrition and biochemistry on the 
day of blood collection using Selectra 2 autoanalyzer (Vital Scientific, 
Spankeren, The Netherlands). Serum glucose was determined 
by the glucose analyzer (YSI, Yellow Springs, OH). Glycosylated 
hemoglobin (HbA1c) levels were measured by immuneturbidimetric 
immunoassay (Unimate; Roche Diagnostics, Indianapolis, IN) with 
a normal range of 4.5-6.1%. Serum triglycerides were measured 
by using a glycerol-3 phosphate oxidase phenol aminoantipyrine, 
with an automated Technicon Axon Analyzer (Bayer Diagnostics, 
Sydney, Australia) using an enzymatic method. Measurement 
of erythrocyte activity of SOD was done using xanthine oxidase 
enzyme and the reagent [2-(p-iodophenol)-3-(p-nitrophenyl)-5-
phenyl tetrazolium chloride (INT)] via enzymatic method (Randox 
kit, Inc. USA).20 GPx activity of erythrocytes lysate was determined 
using hydrogen peroxide and it was expressed in micromoles of 
NADPH/gram of hemoglobin for erythrocytes (Randox kit, Inc. 
USA).21 Serum MDA concentrations were determined using the 
thiobarbituric acid method.22
Total plasma antioxidant capacity was determined by new 
generation colored 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic 
acid radical cation method), (ABTS), (Randox kit, Inc. USA).23 The 
serum vitamin C concentration was determined in venous blood 
under nonfasting conditions by the 2,3-dinitrophenylhydrazine 
method with calorimetric analysis.24 The inter and intra-assay were 
less than 3.5% at all. Statistical analysis was performed with an IBM 
computer using the SPSS 15 statistical software package (SPSS 
Inc., Chicago, IL). The distribution of variables was studied using 
probability plots and the Shapiro-Wilk test. Baseline demographic 
and biochemical values between groups were compared using 
ANOVA. Bonferroni correction was used wherever there was a 
main effect. The differences between groups in ROS scavenging 
enzymes, MDA, TAC or serum concentration of fasting blood 
sugar, TG and vitamin C were analyzed by ANCOVA. Adjustments 
for age, BMI and baseline values were made. Paired t-test was used 
to compare variables within the groups. A value of p<0.05 was 
accepted as significant.
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Results
Eighty one out of the total 100 subjects screened satisfied the entry 
criteria and completed the study. The FBS and HbA1c levels in study 
subjects were 154.49 ± 45.69 and 7.89 ± 1.24, respectively, which 
showed all participants were under fairly good glycemic control. 
The characteristics of the patients confirmed that the groups 
were well matched for all entry criteria (Table 1), and there were 
no significant differences between the groups in either the type or 
the number of antihypertensive or oral hypoglycemic medications. 
The antihypertensive medications taken by the subjects were 
angiotensin-converting enzyme inhibitors (15%), calcium channel 
blockers (8%), angiotensin II receptor antagonists (10%), alpha-
blockers (5%) and non thiazide diuretics (5%).















There were no significant differences between the groups in 
total energy intake, macronutrient intake, body weight, or the 
number of cigarettes smoked at baseline or during the intervention 
(data not shown). Medication doses and physical activity were 
unchanged during the intervention in each group. As for the serum 
scavenging enzymes FBS, HbA1c and TG, the fasting triglyceride 
concentrations at baseline were <500 mg dL-1 in each of the groups. 
There were no significant differences between the groups at baseline 
in TG, FBS, HbA1c, SOD, GPx, MDA, vitamin C or TAC. (Table 
2)
Table 2: Baseline demographic and biochemical characteristics of the patients (n= 81).
Group Characteristic Group 1 Group 2 Group 3 Group 4 p value
NO 21 20 20 20
Age (years) 54 ± 5 53± 5 52 ± 6 50 ± 8 0.515
Weight (kg) 77 ± 9 79 ± 17 76 ± 11 78 ± 17 0.336
Height (cm) 159 ± 8 164 ± 13 160 ± 8 163.9 ± 10 0.199
BMI (kg/m2) 30 ± 3 29 ± 5 29 ± 4 29 ± 4 0.628
Antioxidants
GPx (u/gHb) 53.0 ± 4.3 52.9 ± 7.6 48.1 ± 6.6 50.1 ± 9.6 0.091
SOD (u/gHb) 693.2 ± 31.1 682.6 ± 71.1 704.5 ± 67.7 676.4 ± 97.6 0.269
TAC (mg/dl) 1.0 ± 0.2 1.2 ± 0.3 1.3 ± 0.4 1.3 ± 0.3 0.094
Serum parameters
FBS (mg/dl) 159 ± 50 153 ± 45 149 ± 30 156 ± 55 0.978
HbA1c % 7.7 ± 0.9 7.7 ± 1.4 8.1 ± 0.9 8.1 ± 1.5 0.776
TG (mg/dl) 203 ± 53 164 ± 56 154 ± 45 134 ± 72 0.095
MDA (ng/ml) 1.6 ± 0.8 2.0 ± 0.6 1.3 ± 0.4 1.5 ± 0.3 0.132
Vitamin C (mg/dl) 0.2 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.126
BMI = Body mass index; SOD = Superoxide Dismutase; GPx = Glutathione Peroxidase; TAC = Total Capacity of Antioxidant; FBS= Fasting blood sugar; 
HbA1c = Glycosylated hemoglobin; TG = Teriglyceride; MDA = Malondialdehyde.
After 8 weeks administration of EPA dose of 500 mg/d, the 
concentration of MDA decreased significantly (25%; p=0.04) 
and the activity of the SOD and GPx as well as TAC increased 
(4%; p<0.01), (53%; p<0.01) and (36%; p<0.01), properly during 
intervention (Table 3). The changes in MDA, SOD, GPx and TAC 
were significantly different between group 1 and group 4, respectively 
(Table 4). The levels of TG, FBS and HbA1c decreased (15%; p<0.01), 
(18%; p<0.01), (9%; p<0.01) properly and vitamin C enhanced 
(70%; p<0.01) in group 1 (Table 3), whereas these changes in FBS, 
HbA1c and vitamin C concentration in group 1 in comparison to 
group 4 were not significant. (Table 4)
The vitamin C prescription at the dose of 200 mg/d significantly 
reduced the serum MDA levels (44%; p<0.01), the serum 
concentration of FBS (14%; p<0.01), HbA1c (9%; p=0.03) and 
the serum TG concentration (15%; p=0.02) and increased the 
erythrocyte SOD activity (2%; p<0.01), the erythrocyte GPx activity 
(22%; p<0.01) and the serum concentration of vitamin C (137%; 
p<0.01) during the study (Table 3). There was no significant change 
in the serum concentration of TAC after intervention (Table 3). 
The changes in SOD and GPx erythrocyte activity as well as serum 
vitamin C concentration were significantly different between groups 2 
and 4 (Table 4). The total antioxidant capacity, TG, FBS and HbA1c 
did not show significant differences between group 2 and group 4. 
(Table 4)
The EPA supplementation of 500 mg/d plus 200 mg vitamin 
C showed a significant increment for SOD (3%; p<0.01), for GPx 
(52%; p<0.01) and a significant decrease of 9% (p=0.03) for FBS, 
12% (p<0.01) for HbA1c and (17%; p<0.01) for TG during the study 
(Table 3). No significant changes were seen in the concentrations 
of MDA, vitamin C and TAC before and after the intervention in 
group 3 (Table 3). The changes in SOD and GPx were significantly 
different in group 3 compared to group 4 (Table 4), but there was 
no significant change in MDA, TAC, FBS, HbA1c, TG and vitamin 
C serum concentrations in group 3 compared to group 4. (Table 4)
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Table 3: Changes in variables along among the study groups following intervention.
Variables Group 1 Group 2 Group 3 Group 4
before after before after before after before after
MDA (ng/ml) 1.7 ± 0.8 1.2 ± 0.2# 2.0 ± 0.6 1.1 ± 0.3* 1.3 ± 0.4 1.1 ± 0.3 1.5 ± 0.5 1.7 ± 0.2
SOD (U/gHb) 693.9 ±3 1.1 720.6 ± 29.4* 682.6 ± 71.1 694.9 ± 70.6* 704.5 ± 67.7 726.9 ± 68.7* 676.4 ± 97.6 678.4 ± 97.3
GPx (U/gHb) 53.1 ± 4.3 81.5 ± 2.8* 52.9 ± 7.6 64.7 ± 8.3* 48.1 ± 6.9 73.2 ± 6.2* 50.1 ± 9.6 52.1 ± 9.6
TAC (mg/dl) 1.0 ± 0.2 1.4 ± 0.3* 1.2 ± 0.3 1.1 ± 0.2 1.3 ± 0.4 1.3 ± 0.3 1.3 ± 0.3 1.0 ± 0.3
FBS (mg/dl) 159.4 ± 50.7 130.4 ± 37.0* 153.4 ± 45.0 132.6 ± 35.1* 149.2 ± 30.2 136.0 ± 38.0# 155.7 ± 55.4 135.2 ± 49.6*
HbA1C % 7.7 ± 0.9 7.0 ± 1.2* 7.7 ± 1.4 7.1 ± 1.1# 8.1 ± 0.9 7.1 ± 1.1* 8.1 ± 1.6 7.1 ± 0.9#
TG (mg/dl) 203.1 ± 53.1 171.8 ± 45.0* 163.7 ± 56.4 139.5 ± 46.9# 153.6 ± 45.3 128.1 ± 46.9* 134.1 ± 71.6 115.5 ± 73.8*
VitC (mg/dl) 0.2 ± 0.2 0.4  ± 0.04* 0.3 ± 0.1 0.6 ± 0.2* 0.3 ± 0.1 0.3 ± 0.03 0.2  ± 0.1 0.2 ± 0.03
*Significant difference in respect to baseline (by paired t-test): p<0.01. mean ± SD
# Significant difference in respect to baseline (by paired t-test): p<0.05. mean ± SD
[EPA= eicosapentaenoic acid; MDA= Malondialdehyde; SOD= Superoxide Dismutase; G-PX= Glutathione Peroxidase; TAC = Total Capacity of Antioxidant; 
HbA1c = Glycosylated hemoglobin; FBS= Fasting blood sugar; TG= Triglyceride].
Table 4: Differences in variables at the end of the study following intervention between the groups.
Variables Group 1 Group 2 Group 3 Group 4 p value
MDA (ng/mL) -0.4 ± 0.8* -0.9 ± 0.7* -0.2 ± 0.5 0.3 ± 0.6 <0.01
SOD (U/gHb) 27.4 ± 10.2* 12.3 ± 14.0* 23.5 ± 5.9* 1.9 ± 1.1 0.01
GPx (U/gHb) 28.4 ± 2.5* 11.8 ± 2.7* 25.2 ± 0.8* 2.0 ± 0.0 <0.01
TAC (mg/dL) 0.4 ± 0.4* -0.1 ± 0.4 0.02 ± 0.4 -0.2 ± 0.4 0.04
FBS(mg/dL) -29.0 ± 29.1 -20.7 ± 25.4 -13.2 ± 22.1 -20.5 ± 26.1 0.26
HbA1c % -0.7 ± 0.9 -0.7 ± 1.2 -1.0 ± 0.7 -1.0 ± 1.6 0.74
TG (mg/dL) -31.3 ± 31.3* -24.2 ± 40.6 -25.5 ± 18.4 -18.6 ± 21.5 0.02
Vitamin C(mg/dL) 0.2 ± 0.2 0.4 ± 0.2* -0.05 ± 0.1 -0.03 ± 0.04 0.04
x-bar ± SD. General linear model (ANCOVA) was used to assess treatment effects between groups adjusted for age, BMI, duration of diagnosed diabetes and 
baseline valuse. Bonferroni correction was used wherever there is a main effect. *Significant changes for each of the three treatment groups relative to the placebo group. 
[EPA= eicosapentaenoic acid; MDA= Malondialdehyde; SOD= Superoxide Dismutase; G-PX= Glutathione Peroxidase; TAC= Total Capacity of Antioxidant; 
FBS= Fasting blood sugar; HbA1c = Glycosylated hemoglobin; TG= Triglyceride].
Discussion
Glucotoxicity and lipotoxicity are culprit of oxidative stress in 
diabetic patients.5,6 In this study, EPA prescription in the pure form 
decreased the serum concentration of MDA in diabetic patients. In 
accordance with present findings, a significant reduction in MDA 
concentration has been reported by Kesavulu sequel n-3 fatty acids 
prescription in diabetic patients.25 The antioxidative properties 
of the pure EPA in this study could be attributed to significant 
reduction of TG concentrations following EPA prescription, which 
alone can play a major role in the prevention of lipid oxidation. 
Accordingly, it has previously been reported that a lipid-lowering 
agent, gemfibrozil, significantly reverses the excess lipid peroxidation 
in plasma and vascular tissue without significant changes in glucose 
metabolism and antioxidant enzymes in diabetic rats.26
Brude et al. in corroboration with current results reported 
significant reduction of MDA levels following EPA prescription 
in diabetic patients. They believed that the reduced oxidation rates 
following n-3 fatty acids consumption were due to tight packing 
of EPA and docosahexaenoic acid (DHA) in the lipid membrane 
complex which provides fewer double bonds for interaction with 
free radicals.27 Higgins and Brude advocated that the antioxidant 
property of n-3 fatty acids based on increased plasma and platelet 
concentrations of β-carotene as an antioxidant marker and 
reduction of MDA is observed only in long term studies (more than 
6 weeks). They believed that adaptive compensatory mechanisms 
that are involved in decreased lipid peroxidation are activated only 
in long-term intervention in contrast to short term supplementation 
of n-3 fatty acids.27,28 Decreased inflammations and execution 
of free radical formation in white blood cells following n-3 fatty 
acid consumption has also been assumed by Trevor to explain 
the reduction of lipid peroxidation.29 The combination of vitamin 
C and EPA in this research showed no significant changes in the 
concentration of MDA during the study. In line with the result 
of this study, Sarbolouki et al. depicted an insignificant change in 
serum MDA level sequel to the prescription of EPA combined with 
other antioxidants in diabetic patients.30
In this research, the administration of EPA in its pure form as 
well as in conjunction with vitamin C increased the erythrocyte 
SOD activity. In accordance with the present study, Rahman et al. 
advocated an elevated level of SOD in mice after raising n-3 fatty 
acid serum concentration.12 Other findings indicate that EPA 
may reduce ROS production via upregulation of mitochondrial 
regulators of hydrogen peroxide generation.31 Another mechanism 
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explained the enhancement of SOD following EPA prescription 
involves the findings of Rahman et al. which demonstrated a 
positive significant association between n-3 fatty acids intake and 
higher levels of sirtuin expression.13 It has been reported that 
sirtuin regulates the enzymatic properties of SOD in detoxifying 
mitochondrial superoxide.32
The GPx is another mitochondrial antioxidant enzyme that has 
been increased significantly along the study following prescription 
of EPA combined with vitamin C or without vitamin C. In 
corroboration with the present study, a significant elevated GPx 
activity has been shown by Kesavulu et al. in diabetic patients after 
n-3 fatty acids prescription.25 After 8 weeks of EPA prescription 
in the pure form not in combination with vitamin C, the total 
antioxidant activity was significantly augmented. The current results 
agree with the findings of García-Alonso et al. which implicate that 
the serum antioxidant status improved following n-3 fatty acids 
prescription, and revealed an increase in total antioxidant capacity.14 
EPA participates in cell membrane phospholipids and intact 
lipoproteins such as low density lipoprotein (LDL). Membrane 
phospholipids are substrates for the production of second 
messengers resembling diacylglycerol, and it has been demonstrated 
that the fatty acid composition of such second messengers, which 
is formed by the precursor phospholipid, can manipulate their 
antioxidant properties.33
The data from the current study indicates that the fasting blood 
glucose did not change between the groups after intervention. 
There are controversies concerning the impact of n-3 fatty acids on 
blood sugar.34,35 Woodman and colleagues showed augmentation 
of fasting blood sugar after supplementation of 4000 mg EPA and 
4000 mg DHA.35 It seems higher doses of EPA prescription have 
been associated with increments of FBS in animal and human 
researches.35 Furthermore, these discrepancies could be explained 
by genetic variations in the population of the studies. Schafer and 
his group showed genetic variants of the fatty acid desaturase 1/2 
gene cluster that differently convert n-3 and n-6 PUFA catalyzed by 
the Δ5 and Δ6 desaturase.36
The relationship between type 2 diabetes and higher triglyceride 
levels as well as the hypotriglyceridemic effect of n-3 fatty acids 
are well established and could be found elsewhere.37,38 In this 
study, a similar result based on the reduced TG concentration 
following EPA prescription was found. A mechanism to explain 
the hypotriglyceridemic effects of n-3 fatty acids in humans has 
not been clarified. Recently, a working model was developed 
at the gene transcriptional level, which involves four metabolic 
nuclear receptors.39 These include liver X receptor, hepatocyte 
nuclear factor-4 alpha (HNF-4 alpha), farnesol X receptor, and 
peroxisome proliferators-activated receptor (PPARs). Each of these 
receptors is regulated by sterol receptor element binding protein-
1c (SREBP-1c), a hepatic gene transcription factor that stimulates 
synthesis of the lipogenic enzymes involved in this pathway.40 
N-3 fatty acids elicit hypotriglyceridemic effects by coordinately 
suppressing hepatic lipogenesis through reducing levels of SREBP-
1c, upregulating fatty oxidation in the liver and skeletal muscle 
through PPAR activation, and enhancing flux of glucose to glycogen 
through down regulation of HNF-4 alpha. The net result is the 
repartitioning of metabolic fuel from triglyceride storage toward 
oxidation, thereby reducing the substrate available for Very-Low-
Density Lipoprotein (VLDL) synthesis.39 Interestingly, if  the 
consequences of reduced TG concentration decrease the oxidation 
of fatty acids, intramitochondrial NADH/NAD+ ratio diminishes 
and the formation of ROS in different cells lessen.2-4
In this research, administration of vitamin C showed a significant 
increase in SOD and GPx erythrocyte activity. Vitamin C is able 
to modulate immune responses in several ways, for instance, by 
modulating leukocyte function and lymphocyte proliferation.41 
There are several reports in keeping with this study demonstrating 
a significant enhancement in SOD and GPx activity following 
vitamin C supplementation.42 Bernardo et al. have recently reported 
that administration of vitamin C in small-bowel mucosal biopsy 
organ culture system prevents free radical cytotoxicity and enhances 
scavenging enzymes such as superoxide dismutase, glutathione 
peroxidase and catalase.43 The second line of defense against 
oxidant-induced cellular injury is provided by low molecular weight 
scavengers such as thiols, especially reduced glutathione, alpha-
tocopherol (vitamin E), vitamin C, carotenoids, methionine and 
taurine.44 Frei et al. showed that ascorbic acid is more effective than 
protein thiols, bilirubin, urate or tocopherol, as an antioxidant in 
the plasma with an in vitro system.45 The results of this study also 
showed more reduction in the serum MDA concentration after 
EPA supplementation compared to vitamin C. (Table 4)
The findings in the current study showed that a combination of 
vitamin C and EPA did not improve antioxidant properties of EPA 
revealed by inert impact on serum MDA and TAC levels. It should 
be mentioned that vitamin C has pro-oxidative and antioxidative 
properties. Podmore et al. described the potential pro-oxidant 
effects of daily supplementation with 500 mg of vitamin C on DNA 
base oxidation in vivo.46 Rahman et al. also showed that iron and 
vitamin C co-supplementation increases oxidative damage to DNA 
in healthy volunteers.47 Based on this research, it is hypothesized 
that the pro-oxidative property of vitamin C may increase oxidation 
of highly double bound n-3 fatty acids and also eliminate the 
antioxidative influence of EPA recognized by the reduction of 
MDA. 
It is worth mentioning that serum EPA concentration was not 
determined in the four groups at the beginning and throughout 
the study. As a limitation of this study, it should be taken into 
consideration that measuring EPA serum concentration at the 
beginning and during the study would make this study more valid.
Conclusion
Overall, the prescription of EPA at the dose of 500 mg/day did 
not improve hyperglycemia but it can reduce oxidative stress in 
type 2 diabetic patients by activating antioxidant enzymes (SOD, 
GPx) and increasing the total antioxidant capacity. Vitamin C in 
accordance with EPA has shown antioxidative characteristics in 
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type 2 diabetic patients. A combination of vitamin C and EPA did 
not improve the antioxidant property of EPA. 
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